

Carlo Vancheri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4847366/publications.pdf>

Version: 2024-02-01

134
papers

6,370
citations

57758

44
h-index

76900

74
g-index

138
all docs

138
docs citations

138
times ranked

8176
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. <i>Rheumatology</i> , 2022, 61, 1600-1609. | 1.9 | 53 |
| 2 | Identifying the Risk of Acute Exacerbation in Idiopathic Pulmonary Fibrosis: Another Step Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, , . | 5.6 | 0 |
| 3 | Nintedanib in IPF: Post hoc Analysis of the Italian FIBRONET Observational Study. <i>Respiration</i> , 2022, 101, 577-584. | 2.6 | 6 |
| 4 | "Usual" interstitial pneumonia with autoimmune features: a prospective study on a cohort of idiopathic pulmonary fibrosis patients.. <i>Clinical and Experimental Rheumatology</i> , 2022, , . | 0.8 | 0 |
| 5 | A New Method for the Assessment of Myalgia in Interstitial Lung Disease: Association with Positivity for Myositis-Specific and Myositis-Associated Antibodies. <i>Diagnostics</i> , 2022, 12, 1139. | 2.6 | 5 |
| 6 | Clinical and radiological features of lung disorders related to connective-tissue diseases: a pictorial essay. <i>Insights Into Imaging</i> , 2022, 13, . | 3.4 | 12 |
| 7 | The DIAMORFOSIS (DIAGnosis and Management Of lung cancerR and FibrOSIS) survey: international survey and call for consensus. <i>ERJ Open Research</i> , 2021, 7, 00529-2020. | 2.6 | 22 |
| 8 | Suggestions for lung function testing in the context of COVID-19. <i>Respiratory Medicine</i> , 2021, 177, 106292. | 2.9 | 14 |
| 9 | Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. <i>European Respiratory Review</i> , 2021, 30, 210026. | 7.1 | 17 |
| 10 | PerFECT 2.0: A Web-Based Platform Designed to Facilitate and Support the Diagnosis of Patients with Idiopathic Pulmonary Fibrosis in Italy. <i>Pulmonary Therapy</i> , 2021, 7, 267-279. | 2.2 | 0 |
| 11 | Rethinking Idiopathic Pulmonary Fibrosis. <i>Clinics in Chest Medicine</i> , 2021, 42, 263-273. | 2.1 | 1 |
| 12 | Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. <i>Advances in Therapy</i> , 2021, 38, 4040-4056. | 2.9 | 6 |
| 13 | Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association. <i>Journal of Clinical Medicine</i> , 2021, 10, 2548. | 2.4 | 8 |
| 14 | Quantitative Evaluation of Fibrosis in IPF Patients: Meaning of Diffuse Pulmonary Ossification. <i>Diagnostics</i> , 2021, 11, 113. | 2.6 | 2 |
| 15 | Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting. <i>Frontiers in Pharmacology</i> , 2021, 12, 790204. | 3.5 | 13 |
| 16 | Assessment of Lung Cancer Development in Idiopathic Pulmonary Fibrosis Patients Using Quantitative High-Resolution Computed Tomography. <i>Journal of Thoracic Imaging</i> , 2020, 35, 115-122. | 1.5 | 3 |
| 17 | The Morphological Domain Does Not Affect the Rate of Progression to Defined Autoimmune Diseases in Patients With Interstitial Pneumonia With Autoimmune Features. <i>Chest</i> , 2020, 157, 238-242. | 0.8 | 18 |
| 18 | Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary SjÖsgrén's syndrome: A systematic review from the Italian Society of Rheumatology. <i>Autoimmunity Reviews</i> , 2020, 19, 102447. | 5.8 | 59 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. <i>Microorganisms</i> , 2020, 8, 977. | 3.6 | 41 |
| 20 | Circulating Coding and Long Non-Coding RNAs as Potential Biomarkers of Idiopathic Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8812. | 4.1 | 21 |
| 21 | Resumption of respiratory outpatient services in the COVID-19 era: Experience from Southern Italy. <i>American Journal of Infection Control</i> , 2020, 48, 1087-1089. | 2.3 | 9 |
| 22 | Multidisciplinary Approach to Interstitial Lung Diseases: Nothing Is Better than All of Us Together. <i>Diagnostics</i> , 2020, 10, 488. | 2.6 | 1 |
| 23 | Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. <i>Lancet Respiratory Medicine</i> , 2020, 8, 925-934. | 10.7 | 198 |
| 24 | The Model for Early COvid-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak. <i>Diagnostics</i> , 2020, 10, 619. | 2.6 | 33 |
| 25 | Cryptogenic Organizing Pneumonia: Evolution of Morphological Patterns Assessed by HRCT. <i>Diagnostics</i> , 2020, 10, 262. | 2.6 | 21 |
| 26 | Cystic Interstitial Lung Diseases: A Pictorial Review and a Practical Guide for the Radiologist. <i>Diagnostics</i> , 2020, 10, 346. | 2.6 | 5 |
| 27 | Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. <i>Respirology</i> , 2020, 25, 1144-1151. | 2.3 | 6 |
| 28 | Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity. <i>European Radiology</i> , 2020, 30, 2669-2679. | 4.5 | 19 |
| 29 | Nailfold Videocapillaroscopy Is a Useful Tool to Recognize Definite Forms of Systemic Sclerosis and Idiopathic Inflammatory Myositis in Interstitial Lung Disease Patients. <i>Diagnostics</i> , 2020, 10, 253. | 2.6 | 14 |
| 30 | Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?. <i>Diagnostics</i> , 2020, 10, 208. | 2.6 | 27 |
| 31 | Morphological Patterns of Sarcoidosis and Clinical Outcome: Retrospective Analysis through a Multidisciplinary Approach. <i>Diagnostics</i> , 2020, 10, 212. | 2.6 | 2 |
| 32 | Quantification of Ground Glass Opacities Can Be Useful to Describe Disease Activity in Systemic Sclerosis. <i>Diagnostics</i> , 2020, 10, 225. | 2.6 | 4 |
| 33 | HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review. <i>Diagnostics</i> , 2020, 10, 244. | 2.6 | 27 |
| 34 | Evolution and treatment of idiopathic pulmonary fibrosis. <i>Presse Medicale</i> , 2020, 49, 104025. | 1.9 | 15 |
| 35 | Astrocytes Modify Migration of PBMCs Induced by I^2 -Amyloid in a Blood-Brain Barrier in vitro Model. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 337. | 3.7 | 15 |
| 36 | Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1146-1153. | 5.6 | 60 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2019, 156, 78-84. | 2.9 | 21 |
| 38 | Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. <i>Advances in Therapy</i> , 2019, 36, 232-243. | 2.9 | 15 |
| 39 | Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. <i>Multidisciplinary Respiratory Medicine</i> , 2019, 14, 17. | 1.5 | 43 |
| 40 | Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!. <i>European Respiratory Journal</i> , 2019, 53, 1900615. | 6.7 | 2 |
| 41 | Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality. <i>Chest</i> , 2019, 155, 972-981. | 0.8 | 32 |
| 42 | Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients. <i>Respiratory Medicine</i> , 2019, 150, 154-160. | 2.9 | 53 |
| 43 | Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2019, 54, 1901188. | 6.7 | 9 |
| 44 | Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. <i>BMC Pulmonary Medicine</i> , 2019, 19, 213. | 2.0 | 19 |
| 45 | The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. <i>European Respiratory Journal</i> , 2019, 53, 1801587. | 6.7 | 50 |
| 46 | Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 126-130. | 0.4 | 6 |
| 47 | Chest imaging using signs, symbols, and naturalistic images: a practical guide for radiologists and non-radiologists. <i>Insights Into Imaging</i> , 2019, 10, 114. | 3.4 | 59 |
| 48 | State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. <i>European Respiratory Review</i> , 2018, 27, 170139. | 7.1 | 47 |
| 49 | Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 10. | 2.6 | 9 |
| 50 | Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 356-363. | 5.6 | 193 |
| 51 | Patients with IPF and lung cancer: diagnosis and management. <i>Lancet Respiratory Medicine</i> , 2018, 6, 86-88. | 10.7 | 67 |
| 52 | Pathobiology of Novel Approaches to Treatment. , 2018, , 25-37. | | 0 |
| 53 | Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. <i>European Respiratory Review</i> , 2018, 27, 180078. | 7.1 | 20 |
| 54 | Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 43. | 1.5 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Quantum-inspired minimum distance classification in a biomedical context. <i>International Journal of Quantum Information</i> , 2018, 16, 1840011. | 1.1 | 12 |
| 56 | Conditioned Media From Glial Cells Promote a Neural-Like Connexin Expression in Human Adipose-Derived Mesenchymal Stem Cells. <i>Frontiers in Physiology</i> , 2018, 9, 1742. | 2.8 | 19 |
| 57 | Role of imaging in progressive-fibrosing interstitial lung diseases. <i>European Respiratory Review</i> , 2018, 27, 180073. | 7.1 | 57 |
| 58 | Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients. <i>International Journal of COPD</i> , 2018, Volume 13, 3131-3139. | 2.3 | 50 |
| 59 | Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 39. | 1.5 | 17 |
| 60 | Comorbidities of IPF: How do they impact on prognosis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 53, 6-11. | 2.6 | 13 |
| 61 | Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2018, 52, 1702593. | 6.7 | 29 |
| 62 | The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2018, 19, 141. | 3.6 | 199 |
| 63 | Neural differentiation of human adipose-derived mesenchymal stem cells induced by glial cell conditioned media. <i>Journal of Cellular Physiology</i> , 2018, 233, 7091-7100. | 4.1 | 32 |
| 64 | Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. <i>Chronic Respiratory Disease</i> , 2017, 14, 140-150. | 2.4 | 19 |
| 65 | Neutrophil-to-Lymphocyte Ratio: An Emerging Marker Predicting Prognosis in Elderly Adults with Community-Acquired Pneumonia. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1796-1801. | 2.6 | 133 |
| 66 | When to start and when to stop antifibrotic therapies. <i>European Respiratory Review</i> , 2017, 26, 170053. | 7.1 | 39 |
| 67 | Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017, 50, 1701157. | 6.7 | 61 |
| 68 | Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. <i>European Respiratory Journal</i> , 2017, 50, 1700936. | 6.7 | 75 |
| 69 | Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 591-598. | 10.7 | 71 |
| 70 | Unmet needs in the treatment of idiopathic pulmonary fibrosis—insights from patient chart review in five European countries. <i>BMC Pulmonary Medicine</i> , 2017, 17, 124. | 2.0 | 77 |
| 71 | Preventive and therapeutic effects of thymosin Î²4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis. <i>Oncotarget</i> , 2016, 7, 33841-33854. | 1.8 | 18 |
| 72 | Cough in idiopathic pulmonary fibrosis. <i>European Respiratory Review</i> , 2016, 25, 278-286. | 7.1 | 82 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | New perspectives on management of idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 108-120. | 2.5 | 31 |
| 74 | Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. <i>BMC Pulmonary Medicine</i> , 2016, 16, 10. | 2.0 | 83 |
| 75 | Idiopathic pulmonary fibrosis and cancer: do they really look similar?. <i>BMC Medicine</i> , 2015, 13, 220. | 5.5 | 92 |
| 76 | Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. <i>BMC Medicine</i> , 2015, 13, 277. | 5.5 | 23 |
| 77 | Idiopathic pulmonary fibrosis and lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 626-633. | 2.6 | 67 |
| 78 | The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2015, 45, 1426-1433. | 6.7 | 146 |
| 79 | Protein profile of exhaled breath condensate determined by high resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 105, 134-149. | 2.8 | 32 |
| 80 | Idiopathic pulmonary fibrosis: An update. <i>Annals of Medicine</i> , 2015, 47, 15-27. | 3.8 | 97 |
| 81 | Effects of thymosin β 4 and its N-terminal fragment Ac-SDKP on TGF- β 2-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 211-221. | 3.1 | 16 |
| 82 | Anti-inflammatory and antifibrotic effects of resveratrol in the lung. <i>Histology and Histopathology</i> , 2015, 30, 523-9. | 0.7 | 29 |
| 83 | IPF, comorbidities and management implications. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2015, 32 Suppl 1, 17-23. | 0.2 | 8 |
| 84 | Altered Surfactant Homeostasis and Alveolar Epithelial Cell Stress in Amiodarone-Induced Lung Fibrosis. <i>Toxicological Sciences</i> , 2014, 142, 285-297. | 3.1 | 40 |
| 85 | Combination therapy: the future of management for idiopathic pulmonary fibrosis?. <i>Lancet Respiratory Medicine</i> , 2014, 2, 933-942. | 10.7 | 128 |
| 86 | Thymosin β 4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice. <i>Immunobiology</i> , 2014, 219, 425-431. | 1.9 | 23 |
| 87 | Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events. <i>Advances in Therapy</i> , 2014, 31, 375-391. | 2.9 | 115 |
| 88 | Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review. <i>Insights Into Imaging</i> , 2014, 5, 347-364. | 3.4 | 42 |
| 89 | Effect of pirfenidone on proliferation, TGF- β 2-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 58, 13-19. | 4.0 | 281 |
| 90 | PI3K p110 β overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition. <i>Laboratory Investigation</i> , 2013, 93, 566-576. | 3.7 | 74 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. <i>Journal of Proteomics</i> , 2013, 85, 109-128. | 2.4 | 64 |
| 92 | Human lung fibroblasts increase CD4(+)CD25(+)Foxp3(+) T cells in co-cultured CD4(+) lymphocytes. <i>Cellular Immunology</i> , 2013, 285, 55-61. | 3.0 | 4 |
| 93 | Differentiation of human adipose stem cells into neural phenotype by neuroblastoma or olfactory ensheathing cells conditioned medium. <i>Journal of Cellular Physiology</i> , 2013, 228, 2109-2118. | 4.1 | 29 |
| 94 | A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. <i>European Respiratory Journal</i> , 2013, 41, 262-269. | 6.7 | 71 |
| 95 | Common pathways in idiopathic pulmonary fibrosis and cancer. <i>European Respiratory Review</i> , 2013, 22, 265-272. | 7.1 | 143 |
| 96 | Thymosin β 4 protects C57BL/6 mice from bleomycin-induced damage in the lung. <i>European Journal of Clinical Investigation</i> , 2013, 43, 309-315. | 3.4 | 28 |
| 97 | Idiopathic Pulmonary Fibrosis. <i>Proceedings of the American Thoracic Society</i> , 2012, 9, 153-157. | 3.5 | 55 |
| 98 | Protective effects of thymosin β 4 in a mouse model of lung fibrosis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1269, 69-73. | 3.8 | 17 |
| 99 | Resveratrol inhibits transforming growth factor- β 1-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through ERK/Akt inhibition and PTEN restoration. <i>Experimental Lung Research</i> , 2011, 37, 162-174. | 1.2 | 50 |
| 100 | Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms. <i>PLoS ONE</i> , 2011, 6, e24663. | 2.5 | 126 |
| 101 | Reactive Oxygen Species Are Required for Maintenance and Differentiation of Primary Lung Fibroblasts in Idiopathic Pulmonary Fibrosis. <i>PLoS ONE</i> , 2010, 5, e14003. | 2.5 | 122 |
| 102 | Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. <i>European Respiratory Journal</i> , 2010, 35, 496-504. | 6.7 | 399 |
| 103 | Antiproliferative effects induced by guanine-based purines require hypoxanthine-guanine phosphoribosyltransferase activity. <i>Biological Chemistry</i> , 2010, 391, 1079-89. | 2.5 | 8 |
| 104 | Acute additive effect of montelukast and beclomethasone on AMP induced bronchoconstriction. <i>Respiratory Medicine</i> , 2010, 104, 1417-1424. | 2.9 | 4 |
| 105 | 16,16-Dimethyl Prostaglandin E2 Efficacy on Prevention and Protection from Bleomycin-Induced Lung Injury and Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2009, 41, 50-58. | 2.9 | 32 |
| 106 | TGF- β 1 targets the GSK-3 β / β -catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. <i>Pharmacological Research</i> , 2008, 57, 274-282. | 7.1 | 180 |
| 107 | Subsegmental Pulmonary Embolism: Value of Thoracic Ultrasound for Diagnosis and Follow-Up. <i>Internal Medicine</i> , 2008, 47, 1415-1417. | 0.7 | 9 |
| 108 | Protective effect of orally administered carnosine on bleomycin-induced lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 292, L1095-L1104. | 2.9 | 63 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Exhaled bronchial cysteinyl leukotrienes in allergic patients. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2007, 7, 25-31. | 2.3 | 6 |
| 110 | Activation of cytosolic phospholipase A2 and 15-lipoxygenase by oxidized low-density lipoproteins in cultured human lung fibroblasts. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2007, 1771, 522-532. | 2.4 | 16 |
| 111 | Astrocyte-like cells as a main target for estrogen action during neuronal differentiation. <i>Molecular and Cellular Neurosciences</i> , 2007, 34, 562-570. | 2.2 | 9 |
| 112 | Effects of TGF β 2 and glucocorticoids on map kinase phosphorylation, IL6/IL1 secretion and cell proliferation in primary cultures of human lung fibroblasts. <i>Journal of Cellular Physiology</i> , 2007, 210, 489-497. | 4.1 | 50 |
| 113 | Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2006, 7, 122. | 3.6 | 47 |
| 114 | Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. <i>Respiratory Research</i> , 2006, 7, 137. | 3.6 | 40 |
| 115 | Endothelin-1 induces proliferation of human lung fibroblasts and IL-11 secretion through an ETA receptor-dependent activation of map kinases. <i>Journal of Cellular Biochemistry</i> , 2005, 96, 858-868. | 2.6 | 48 |
| 116 | The p53-homologue p63 may promote thyroid cancer progression. <i>Endocrine-Related Cancer</i> , 2005, 12, 953-971. | 3.1 | 50 |
| 117 | Interaction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells. <i>Respiratory Research</i> , 2005, 6, 103. | 3.6 | 19 |
| 118 | Inhibition or knock out of Inducible nitric oxide synthase result in resistance to bleomycin-induced lung injury. <i>Respiratory Research</i> , 2005, 6, 58. | 3.6 | 60 |
| 119 | Montelukast protects against bradykinin-induced bronchospasm. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 870-872. | 2.9 | 11 |
| 120 | Bradykinin differentiates human lung fibroblasts to a myofibroblast phenotype via the B2 receptor. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 1242-1248. | 2.9 | 37 |
| 121 | Bradykinin and Tachykinin-induced Leukotriene Release in Airway Virus Infections. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 511-511. | 5.6 | 1 |
| 122 | The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. <i>Allergy and Asthma Proceedings</i> , 2005, 26, 292-8. | 2.2 | 9 |
| 123 | β 2-Amyloid-Activated Cell Cycle in SH-SY5Y Neuroblastoma Cells: Correlation with the MAP Kinase Pathway. <i>Journal of Molecular Neuroscience</i> , 2004, 22, 231-236. | 2.3 | 27 |
| 124 | The lung as a privileged site for the beneficial actions of PGE2. <i>Trends in Immunology</i> , 2004, 25, 40-46. | 6.8 | 284 |
| 125 | Impact of intranasal budesonide on immune inflammatory responses and epithelial remodeling in chronic upper airway inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 37-44. | 2.9 | 40 |
| 126 | Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin a-induced bronchoconstriction. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 833-839. | 2.9 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 703-708. | 2.9 | 63 |
| 128 | Normal Human Lung Fibroblasts Differently Modulate Interleukin-10 and Interleukin-12 Production by Monocytes. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 25, 592-599. | 2.9 | 36 |
| 129 | Different Expression of TNF- α Receptors and Prostaglandin E ₂ Production in Normal and Fibrotic Lung Fibroblasts. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000, 22, 628-634. | 2.9 | 89 |
| 130 | Mitogenic Effect of Nerve Growth Factor (NGF) in LNCaP Prostate Adenocarcinoma Cells: Role of the High- and Low-Affinity NGF Receptors. <i>Molecular Endocrinology</i> , 2000, 14, 124-136. | 3.7 | 6 |
| 131 | Nuclear factor- κ B activation in human monocytes stimulated with lipopolysaccharide is inhibited by fibroblast conditioned medium and exogenous PGE ₂ . <i>FEBS Letters</i> , 1997, 400, 315-318. | 2.8 | 18 |
| 132 | Release of Mast-Cell-derived Mediators after Endobronchial Adenosine Challenge in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 624-629. | 5.6 | 153 |
| 133 | Human Upper Airway Epithelial Cell-Derived Granulocyte-Macrophage Colony-Stimulating Factor Induces Histamine-Containing Cell Differentiation of Human Progenitor Cells. <i>International Archives of Allergy and Immunology</i> , 1991, 95, 376-384. | 2.1 | 34 |
| 134 | "Usual" interstitial pneumonia with autoimmune features: a prospective study on a cohort of idiopathic pulmonary fibrosis patients. <i>Clinical and Experimental Rheumatology</i> , 0, , . | 0.8 | 5 |